The event will prepare investors for the release of SPLASH’s lead-in cohort efficacy data later this year by providing an...
Extends Rani’s projected cash runway into mid-2024SAN JOSE, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani...
Coronavirus Is Not An Outlier In Interconnected Age of Air Travel and Urbanization; TOMI Environmental Partners With Customers To Provide...
VANCOUVER, British Columbia, Aug. 08, 2022 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) is pleased...
-Following internal corroboration of published results on the MyoAAV platform, Sarepta secures exclusive license for Duchenne muscular dystrophy, plus four...
SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a...
BOTHELL, Wash., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has...
SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty...
Conference call to be held today, August 8, 2022 at 8:30 AM ETNEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) --...
Positive topline data in the Phase 2 BrigHtn trial, demonstrating clinically meaningful and statistically significant reduction in blood pressure with...
~ Announced 12-month data on the lower-dose cohort of AMT-130 in Huntington’s disease showed the investigative gene therapy was generally...
98% of 401 Primary Care Physicians confirmed KidneyIntelX has value as a risk decision tool in their adult patients with...
Successfully met the primary endpoint in the BrigHtn trial, delivering a 20.3 mmHg reduction in systolic blood pressure (SBP), or...
Phase 1 Study of TNX-801, a Vaccine in Development for the Prevention of Monkeypox and Smallpox, Expected to Initiate in...
Announced results from two of the ongoing Phase 2 clinical trials of PDS0101 in multiple, difficult-to-treat HPV16-related cancers presented at...
- gavo-cel Phase 1 trial dataset anticipated in September 2022- Initial TC-510 Phase 1 data anticipated in 2H 2022 -...
Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide...
— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — —...
Second quarter revenues of €3.2 billion1, net profit of €1.7 billion and fully diluted earnings per share of €6.45 ($6.872) as well...
Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with...